AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31148099 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine 90 mg/die t.i.d plus placebo b.i.d
Number of subjects: 0
Study 31148099 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 90 mg t.i.d plus choline alphoscerate 1200 mg/die b.i.d
Number of subjects: 0
Study 29142011 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 278
Study 29142011 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate (MED/LC) diet + 28 g walnuts/day
Number of subjects: 278
Study 29142011 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA+)
Number of subjects: 278
Study 29142011 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA+) with MED/LC diet
Number of subjects: 278
Study 29142011 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean/low-carbohydrate (MED/LC) diet
Number of subjects: 278
Study 29142011 — intervention group
Group type: COMPARATOR
Intervention: Weight loss
Number of subjects: 278
Study 28447545 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based self-management support intervention (education, social support, home visits, and telephone calls)
Number of subjects: 157
Study 28447545 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 157
Study 26228998 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline
Number of subjects: 6
Study 26228998 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% albumin
Number of subjects: 6
Study 26228998 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose
Number of subjects: 6
Study 23910712 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase
Number of subjects: 36
Study 23910712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 20613654 — intervention group
Group type: EXPERIMENTAL
Intervention: Female Training (FT)
Number of subjects: 60
Study 20613654 — intervention group
Group type: EXPERIMENTAL
Intervention: Male Training (MT)
Number of subjects: 60
Study 20613654 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 60
Study 20613654 — intervention group
Group type: EXPERIMENTAL
Intervention: Female Training (FT) and Male Training (MT)
Number of subjects: 60
Study 20613654 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FT and MT groups
Number of subjects: 60
Study 18369067 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide
Number of subjects: 15
Study 18369067 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 15
Study 16516077 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting with abciximab
Number of subjects: 1529
Study 16516077 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty with abciximab
Number of subjects: 1529
Study 16516077 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting without abciximab
Number of subjects: 1529
Study 16516077 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty without abciximab
Number of subjects: 1529
Study 12668296 — intervention group
Group type: COMPARATOR
Intervention: Conventional tracheal airway (ETA)
Number of subjects: 172
Study 12668296 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal‐Tracheal Combitube (ETC)
Number of subjects: 172
Study 12668296 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (epinephrine) via ETC
Number of subjects: 172
Study 10518167 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytically oriented partial hospitalization
Number of subjects: 38
Study 10518167 — intervention group
Group type: COMPARATOR
Intervention: Standard psychiatric care (control)
Number of subjects: 38
Study 8594425 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (1 mg of enoxaparin per kilogram of body weight subcutaneously twice daily)
Number of subjects: 500
Study 8594425 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin (intravenous)
Number of subjects: 500
Study 8594425 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 500
Study 8594425 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 500
Study 1748110 — intervention group
Group type: COMPARATOR
Intervention: Unloaded condition (5.2 kg clothing mass)
Number of subjects: 15
Study 1748110 — intervention group
Group type: EXPERIMENTAL
Intervention: External load of 31.5 kg
Number of subjects: 15
Study 1748110 — intervention group
Group type: EXPERIMENTAL
Intervention: External load of 49.4 kg
Number of subjects: 15
Study 7128192 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin at night
Number of subjects: 14
Study 7128192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31868666 — intervention group
Group type: EXPERIMENTAL
Intervention: Choreographed exercise (Choreography group)
Number of subjects: 36
Study 31868666 — intervention group
Group type: COMPARATOR
Intervention: Multimodal physical therapy (Physical Therapy group)
Number of subjects: 36
Study 31587438 — intervention group
Group type: EXPERIMENTAL
Intervention: SystemCHANGETM intervention
Number of subjects: 0
Study 31587438 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (education on healthy living after transplant)
Number of subjects: 0
Study 27055824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ashwagandha (300 mg) twice daily
Number of subjects: 52
Study 27055824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 25266601 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 43
Study 25266601 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 43
Study 24298762 — intervention group
Group type: EXPERIMENTAL
Intervention: Shao's five needling therapy combined with oxygen uptake, aerosol inhalation, and oral administration of prednisone
Number of subjects: 210
Study 24298762 — intervention group
Group type: COMPARATOR
Intervention: Theophylline sustained release tablet combined with oxygen uptake, aerosol inhalation, and oral administration of prednisone
Number of subjects: 210
Study 21904230 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nail (n = 56)
Number of subjects: 104
Study 21904230 — intervention group
Group type: COMPARATOR
Intervention: Large fragment medial plate (n = 48)
Number of subjects: 104
Study 19657820 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored decision support intervention
Number of subjects: 176
Study 19657820 — intervention group
Group type: COMPARATOR
Intervention: Standard menopausal information
Number of subjects: 176
Study 16690347 — intervention group
Group type: EXPERIMENTAL
Intervention: AquaRelease (nelfilcon A with additional PVA)
Number of subjects: 39
Study 16690347 — intervention group
Group type: COMPARATOR
Intervention: ocufilcon B
Number of subjects: 39
Study 15271690 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone injections (100 mg of testosterone enanthate injected weekly)
Number of subjects: 47
Study 15271690 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (45 minutes three times weekly)
Number of subjects: 47
Study 15271690 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone injections + Resistance training
Number of subjects: 47
Study 15271690 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections + Resistance training
Number of subjects: 47
Study 15271690 — intervention group
Group type: COMPARATOR
Intervention: Testosterone injections + No training
Number of subjects: 47
Study 11966550 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine (2 mg.ml(‐1))
Number of subjects: 115
Study 11966550 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine (2 mg.ml(‐1)) with sufentanil (1 microg.ml(‐1))
Number of subjects: 115
Study 9617977 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 395
Study 9617977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 7613799 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter traction for 30 min
Number of subjects: 115
Study 7613799 — intervention group
Group type: COMPARATOR
Intervention: No catheter traction
Number of subjects: 115
Study 2092965 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (30mg, 60mg, or 90mg twice daily)
Number of subjects: 165
Study 2092965 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (12.5 mg/day or 12.5 or 25mg twice daily)
Number of subjects: 165
Study 2092965 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 165
Study 2092965 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 165
Study 2092965 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil and Hydrochlorothiazide
Number of subjects: 165
Study 366257 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 1% with phenylephrine 0.25%
Number of subjects: 2
Study 366257 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine 1%
Number of subjects: 2
Study 6800537 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 908
Study 6800537 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical operation
Number of subjects: 908
Study 6800537 — intervention group
Group type: EXPERIMENTAL
Intervention: Less conventional operations
Number of subjects: 908
Study 6800537 — intervention group
Group type: COMPARATOR
Intervention: Reduction in operation rates
Number of subjects: 908
Study 30239610 — intervention group
Group type: COMPARATOR
Intervention: Baseline plasma 25(OH)D >33.6 ng/mL
Number of subjects: 711
Study 30239610 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma 25(OH)D <20 ng/mL
Number of subjects: 711
Study 29214305 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 15760
Study 27339840 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stents (EES)
Number of subjects: 189
Study 27339840 — intervention group
Group type: COMPARATOR
Intervention: Drug-Eluting Balloons (DEB)
Number of subjects: 189
Study 23800753 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional block with sedation
Number of subjects: 50
Study 23800753 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 50
Study 22479550 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 679
Study 22479550 — intervention group
Group type: COMPARATOR
Intervention: Formula/cows' milk feeding
Number of subjects: 679
Study 20173086 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone Contramid OAD (TzCOAD) 75-375 mg
Number of subjects: 0
Study 17638640 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality monitoring
Number of subjects: 0
Study 17638640 — intervention group
Group type: COMPARATOR
Intervention: Single modality monitoring (intracranial pressure monitoring)
Number of subjects: 0
Study 16127194 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin + exercise (walking for 60 min after heparin injection [3,000 units/day IV for 14 days], n = 6)
Number of subjects: 19
Study 16127194 — intervention group
Group type: COMPARATOR
Intervention: heparin administration only (n = 6)
Number of subjects: 19
Study 16127194 — intervention group
Group type: COMPARATOR
Intervention: exercise only (n = 7)
Number of subjects: 19
Study 11832980 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive epidural analgesia with 8 mL of 0.25% bupivacaine and 2 mL of fentanyl (50 microg/mL) prior to skin incision, followed by an infusion of bupivacaine 0.1% and fentanyl 10 microg/mL at 6 mL/hr.
Number of subjects: 0
Study 11832980 — intervention group
Group type: COMPARATOR
Intervention: Control group received saline in the epidural.
Number of subjects: 0
Study 10420027 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP/Nd:YAG laser treatment
Number of subjects: 204
Study 10420027 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 204
Study 7500327 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise self-efficacy
Number of subjects: 1944
Study 7500327 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous exercise experience, satisfaction with amount of walking, depression, and outcome expectations
Number of subjects: 1944
Study 7500327 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise outcome expectations
Number of subjects: 1944
Study 2261179 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric photoscreener
Number of subjects: 231
Study 2261179 — intervention group
Group type: COMPARATOR
Intervention: Conventional testing
Number of subjects: 231
Study 6106095 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal human tetanus immunoglobulin (TIG) 250 IU
Number of subjects: 97
Study 6106095 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular human tetanus immunoglobulin (TIG) 1000 IU
Number of subjects: 97
Study 31590698 — intervention group
Group type: EXPERIMENTAL
Intervention: C-section
Number of subjects: 205
Study 31590698 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician practices
Number of subjects: 205
Study 31590698 — intervention group
Group type: EXPERIMENTAL
Intervention: Health system characteristics
Number of subjects: 205
Study 31590698 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for improvement
Number of subjects: 205
Study 31345359 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/d zinc (as zinc gluconate) for 12 weeks
Number of subjects: 60
Study 31345359 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study 27770338 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-loaded bone cement (ALBC)
Number of subjects: 39
Study 27770338 — intervention group
Group type: COMPARATOR
Intervention: Bone cement (BC)
Number of subjects: 39
Study 27770338 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ALBC and BC
Number of subjects: 39
Study 26441467 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching with mobile phone monitoring
Number of subjects: 131
Study 26441467 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching without mobile phone monitoring
Number of subjects: 131
Study 26441467 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health coaching)
Number of subjects: 131
Study 23381840 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rivaroxaban
Number of subjects: 34
Study 23381840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 24843514 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for diabetes evaluated as odds ratios adjusted for potential confounding factors by logistic regression
Number of subjects: 9223
Study 24843514 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, smoking (both past and current), family history of diabetes in men
Number of subjects: 9223
Study 24843514 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index, family history of diabetes, hypertension in women
Number of subjects: 9223
Study 24843514 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HbA1c value
Number of subjects: 9223
Study 19739499 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobloc appliance treatment
Number of subjects: 41
Study 19739499 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 41
Study 17966440 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI plus antiarrhythmic (Propafenona, 450 mg daily)
Number of subjects: 36
Study 17966440 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic (Propafenona, 450 mg daily)
Number of subjects: 36
Study 15073669 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg famciclovir 3 times daily
Number of subjects: 177
Study 15073669 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg famciclovir 3 times daily
Number of subjects: 177
Study 15073669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 15073669 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir (both dosages)
Number of subjects: 177
Study 12049083 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk filling technique
Number of subjects: 27
Study 12049083 — intervention group
Group type: COMPARATOR
Intervention: Three horizontal increments technique
Number of subjects: 27
Study 12049083 — intervention group
Group type: COMPARATOR
Intervention: Pre‐polymerized composite inserts technique
Number of subjects: 27
Study 9380326 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral beta carotene for at least 6 months
Number of subjects: 39
Study 9380326 — intervention group
Group type: COMPARATOR
Intervention: Placebo for at least 6 months
Number of subjects: 39
Study 8217750 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical all‐trans‐retinoic acid (0.1% and 0.025% cream formulations)
Number of subjects: 0
Study 8217750 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical all‐trans‐retinoic acid (0.001 to 0.025% concentrations)
Number of subjects: 0
Study 8217750 — intervention group
Group type: COMPARATOR
Intervention: Sodium lauryl sulphate
Number of subjects: 0
Study 3302542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime administered intraincisionally before surgery and immediately after surgery (total 5,250 mg)
Number of subjects: 52
Study 3302542 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime administered only postoperatively (total 5,250 mg)
Number of subjects: 52
Study 31414192 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilepsy Self-Management Scale (ESMS) lifestyle management
Number of subjects: 100
Study 31414192 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilepsy Self-Management Scale (ESMS) safety management
Number of subjects: 100
Study 31414192 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 100
Study 29262978 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline alone
Number of subjects: 435
Study 29262978 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline combined with nicotine replacement therapy (NRT)
Number of subjects: 435
Study 26056164 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal training
Number of subjects: 518
Study 26056164 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prenatal training)
Number of subjects: 518
Study 22716279 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic elastic separators placed between the second premolar and first molar (compression site)
Number of subjects: 10
Study 22716279 — intervention group
Group type: COMPARATOR
Intervention: Control site (contralateral quadrant)
Number of subjects: 10
Study 22272505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential presentation mode condition (visual working memory)
Number of subjects: 0
Study 22272505 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential delay condition (visual working memory)
Number of subjects: 0
Study 22272505 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation condition (both visual and spatial working memory)
Number of subjects: 0
Study 22272505 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous baseline condition (visual working memory)
Number of subjects: 0
Study 22272505 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous delay condition (visual working memory)
Number of subjects: 0
Study 19811624 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary diabetes care teams (IDCT)
Number of subjects: 2495
Study 19811624 — intervention group
Group type: EXPERIMENTAL
Intervention: IDCT in Advanced Quality Improvement Program (AQIP)
Number of subjects: 2495
Study 19811624 — intervention group
Group type: COMPARATOR
Intervention: Usual Quality Improvement Program (UQIP)
Number of subjects: 2495
Study 17027560 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 302
Study 17027560 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular angiography
Number of subjects: 302
Study 12631048 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 microg premedication
Number of subjects: 32
Study 12631048 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral antacid - algel hydroxide 300 mg)
Number of subjects: 32
Study 10694308 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 1% emulsion-gel
Number of subjects: 65
Study 10694308 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole 2% cream
Number of subjects: 65
Study 8884758 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (APZ) 1 mg/day orally for 3 days
Number of subjects: 12
Study 8884758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1393414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 169
Study 1393414 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cholecystography (OCG)
Number of subjects: 169
Study 1393414 — intervention group
Group type: COMPARATOR
Intervention: Combination of US and OCG
Number of subjects: 169
Study 6321588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d. for 6 weeks
Number of subjects: 73
Study 6321588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 6321588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 73
Study 31549872 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30419927 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MeD)
Number of subjects: 188
Study 30419927 — intervention group
Group type: COMPARATOR
Intervention: FTO gene influence
Number of subjects: 188
Study 25720069 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant II Turbo system
Number of subjects: 0
Study 25720069 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillarys 2 Flex Piercing system
Number of subjects: 0
Study 25720069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra2 system
Number of subjects: 0
Study 25720069 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-8160 system
Number of subjects: 0
Study 24118853 — intervention group
Group type: EXPERIMENTAL
Intervention: 33°C temperature control for 24 hours after cardiac arrest
Number of subjects: 0
Study 24118853 — intervention group
Group type: EXPERIMENTAL
Intervention: 36°C temperature control for 24 hours after cardiac arrest
Number of subjects: 0
Study 24118853 — intervention group
Group type: COMPARATOR
Intervention: Myocardial infarction controls
Number of subjects: 0